Home

Novartis

Pharma Ups the Dividend Ante

Sat, 01/01/2011 - 10:41 by Brian Orelli

 There's no way to sugarcoat this: It was not a pretty year for pharmaceutical companies. While the S&P saw substantial gains over the last year, with the exception of Bristol-Myers Squibb (NYSE: BMY) and Novartis (NYSE: NVS), every other major pharmaceutical company listed on the U.S. exchange saw their shares decrease. And neither of the two that were in positive territory actually surpassed the S&P 500.

 

Corcept May Have Hit Pay Dirt

Fri, 12/24/2010 - 12:24 by Brian Orelli

After failing to show a statistically significant effect for treating the psychotic features of psychotic depression in three individual clinical trials, Corcept Therapeutics (Nasdaq: CORT) finally found something that its drug candidate, Corlux, is good at: treating Cushing's syndrome.

Our Drug Is Better Than Your Drug

Wed, 12/22/2010 - 11:41 by Brian Orelli

"I am highly confident that at the end of the day, when all the cards are on the table, we will be, not only the JAK1 and 2 inhibitor that is two to three years ahead of any potential competition, but that we have the best compound."
-- Paul Friedman, President and CEO of Incyte (Nasdaq: INCY).

FDA warns Novartis about Facebook widget

Sun, 08/08/2010 - 19:03 by Neka Sehgal

The use of Facebook, a popular social network site, by Novartis Pharmaceuticals to promote its leukemia drug Tasigna has met the disapproval of the US Food and Drug Administration (FDA).

Novartis Test Drives Biotech Startup Adimab's Drug Discovery Engine

Fri, 07/09/2010 - 23:39 by Motley Fool

Lebanon, NH-based biotech startup Adimab has grown the ranks of its Big Pharma collaborators, which are coveted for their deep pockets and other resources they bring to smaller firms. Swiss drug giant Novartis (NYSE: NVS)has inked a research agreement with Adimab to access the startup's synthetic immune system of sorts that churns out potential antibody drugs.

FDA approves Novartis' first oral multiple sclerosis drug

Fri, 06/11/2010 - 13:22 by Manmeet kaur

The U.S. Food and Drug Administration (FDA) advisory panel approved the first line treatment for multiple sclerosis (MS) Gilenia is the first oral drug that Novaritis, a German drug maker, would sell under this brand name.

First MS pill under consideration

Sat, 06/05/2010 - 11:27 by Rakhi

Washington -- A drug by Novartis could become the first pill sold on the U.S. market for the treatment of multiple sclerosis, authorities said.

Gilenia, also called fingolimod, has been shown to significantly reduce relapses in patients with relapsing remitting multiple sclerosis, Novartis officials said.

A federal advisory panel is to consider next week whether the Food and Drug Administration should approve the drug for sale in the United States, the San Antonio Express-News reported Friday.

Fingolimod is one of two multiple sclerosis drugs in pill form that have been submitted for FDA approval. Currently, drugs for multiple sclerosis must be injected or infused by patients.

Novartis to appeal sex discrimination case

Wed, 05/19/2010 - 09:09 by harsheeb

New York -- Drug giant Novartis Pharmaceuticals Corp. said it would appeal a court ruling in Manhattan that found the company guilty of widespread sexual discrimination.

The company issued a statement that said it was "disappointed in the jury's verdict and the $3.3 million award to the plaintiffs," the New York Daily News reported Tuesday.

A lawyer for the plaintiffs, Katherine Kimpel, said Novartis "is a company stuck in a different century." Awards in the case for 12 plaintiffs ranged from $50,000 to $600,000, but the total could be far higher when a decision is made how much to award 5,600 women who signed onto a class-action case against the company.

Novartis to purchase 52 percent of Alcon

Tue, 01/05/2010 - 08:05 by harsheeb

Geneva -- Swiss pharmaceutical giant Novartis International said Monday it would exercise an option to buy 52 percent of eye care company Alcon for $28.1 billion.

Novartis set up the deal in April 2008, when it purchased 23 percent of Alcon for $10.4 billion, The Times of London Online reported Monday.

The price per share in the new deal is set at $180 per share, up from the $143 per share it paid for the first 23 percent. In addition, it is offering 2.8 Novartis shares for the shares it has yet to purchase, which would value the outstanding Alcon shares at $137.

Alcon is a leading producer of contact lens solutions and medical devices pertaining to eye surgery.

Swine Flu Doesn't Need to Save Novartis

Sat, 10/24/2009 - 10:08 by Brian Orelli

Novartis (NYSE: NVS) has lots of moving parts, making it tricky to analyze, but it looks to me like the overall picture is pretty healthy.